BRPI0210076B8 - preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato - Google Patents
preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinatoInfo
- Publication number
- BRPI0210076B8 BRPI0210076B8 BRPI0210076A BRPI0210076B8 BR PI0210076 B8 BRPI0210076 B8 BR PI0210076B8 BR PI0210076 A BRPI0210076 A BR PI0210076A BR PI0210076 B8 BRPI0210076 B8 BR PI0210076B8
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- tocopherol
- alpha
- influenza virus
- influenza
- Prior art date
Links
- 101710154606 Hemagglutinin Proteins 0.000 title abstract 5
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title abstract 5
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title abstract 5
- 101710176177 Protein A56 Proteins 0.000 title abstract 5
- 239000000185 hemagglutinin Substances 0.000 title abstract 5
- 241000712461 unidentified influenza virus Species 0.000 title abstract 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 229940087168 alpha tocopherol Drugs 0.000 title abstract 2
- 229960003971 influenza vaccine Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 title abstract 2
- 229960000984 tocofersolan Drugs 0.000 title abstract 2
- 239000002076 α-tocopherol Substances 0.000 title abstract 2
- 235000004835 α-tocopherol Nutrition 0.000 title abstract 2
- 206010022000 influenza Diseases 0.000 abstract 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 abstract 2
- 229960004906 thiomersal Drugs 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000011732 tocopherol Substances 0.000 abstract 1
- 229960001295 tocopherol Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0113083A GB0113083D0 (en) | 2001-05-30 | 2001-05-30 | Novel compounds |
| GB0113083.0 | 2001-05-30 | ||
| GB0204116A GB0204116D0 (en) | 2002-02-21 | 2002-02-21 | Novel vaccine composition |
| GB0204116.8 | 2002-02-21 | ||
| PCT/EP2002/005883 WO2002097072A2 (en) | 2001-05-30 | 2002-05-29 | Influenza vaccine composition |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BR0210076A BR0210076A (pt) | 2004-06-22 |
| BRPI0210076A8 BRPI0210076A8 (pt) | 2017-05-23 |
| BRPI0210076B1 BRPI0210076B1 (pt) | 2020-01-07 |
| BRPI0210076B8 true BRPI0210076B8 (pt) | 2021-05-25 |
Family
ID=30445235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0210076-2 BRPI0210076B8 (pt) | 2001-05-30 | 2002-05-29 | preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7316813B2 (enExample) |
| EP (3) | EP2495314A1 (enExample) |
| JP (1) | JP4074582B2 (enExample) |
| KR (1) | KR100871021B1 (enExample) |
| CN (2) | CN101069744B (enExample) |
| AR (1) | AR036039A1 (enExample) |
| AT (1) | ATE420159T1 (enExample) |
| AU (2) | AU2006200742C9 (enExample) |
| BR (1) | BRPI0210076B8 (enExample) |
| CA (1) | CA2448208C (enExample) |
| CO (1) | CO5540349A2 (enExample) |
| CY (1) | CY1108930T1 (enExample) |
| CZ (1) | CZ298697B6 (enExample) |
| DE (1) | DE60230760D1 (enExample) |
| DK (1) | DK1407008T3 (enExample) |
| ES (1) | ES2318020T3 (enExample) |
| FR (1) | FR13C0072I1 (enExample) |
| HU (1) | HU229368B1 (enExample) |
| IL (2) | IL158931A (enExample) |
| MX (1) | MXPA03010944A (enExample) |
| MY (1) | MY134424A (enExample) |
| NO (1) | NO335212B1 (enExample) |
| NZ (1) | NZ529755A (enExample) |
| PL (1) | PL206435B1 (enExample) |
| PT (1) | PT1407008E (enExample) |
| SI (1) | SI1407008T1 (enExample) |
| TW (1) | TWI228420B (enExample) |
| WO (1) | WO2002097072A2 (enExample) |
| ZA (1) | ZA200309250B (enExample) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL355287A1 (en) * | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
| US20060110406A1 (en) | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
| CA2807534A1 (en) | 2003-02-25 | 2005-02-17 | Medimmune Vaccines, Inc. | Methods of producing influenza vaccine compositions |
| RS51665B (sr) | 2004-09-09 | 2011-10-31 | Novartis Vaccines And Diagnostics Gmbh. | Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa |
| EP1796719B1 (en) * | 2004-10-06 | 2014-12-03 | MedImmune, LLC | Refrigerator-temperature stable influenza vaccine compositions |
| AU2005314563B2 (en) * | 2004-11-03 | 2011-06-30 | Seqirus UK Limited | Influenza vaccination |
| US9161905B2 (en) * | 2005-01-12 | 2015-10-20 | Ocular Research Of Boston, Inc. | Dry eye treatment |
| DK1861120T3 (en) * | 2005-03-23 | 2016-07-25 | Glaxosmithkline Biologicals Sa | Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response |
| BRPI0614254A2 (pt) * | 2005-08-02 | 2011-03-15 | Novartis Vaccines & Diagnostic | redução de interferência entre adjuvantes contendo óleo e antìgenos contendo tensoativos |
| ATE494906T1 (de) | 2005-11-01 | 2011-01-15 | Novartis Vaccines & Diagnostic | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna |
| US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| WO2007052055A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| NZ594482A (en) | 2005-11-04 | 2012-11-30 | Novartis Vaccines & Diagnostic | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant |
| CA2628424A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted influenza vaccines including cytokine-inducing agents |
| KR20080069232A (ko) | 2005-11-04 | 2008-07-25 | 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. | 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼 |
| ES2377884T3 (es) | 2005-11-04 | 2012-04-02 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| PL2478916T3 (pl) | 2006-01-27 | 2020-11-16 | Seqirus UK Limited | Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy |
| WO2007110776A1 (en) * | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
| BRPI0621886B1 (pt) | 2006-07-17 | 2021-09-21 | Glaxosmithkline Biologicals S.A | Composição de vacina contra influenza monovalente, kit, método para a produção de uma composição de vacina contra influenza para uma situação pandêmica ou uma situação pré- pandêmica, e, usos de um antígeno de vírus da influenza ou preparação antigênica do mesmo e de um adjuvante em emulsão óleo-em-água, de um antígeno de vírus da influenza pandêmica ou preparação antigênica do antígeno de hemaglutinina do vírus da influenza e de um adjuvante em emulsão óleo-em-água e de um antígeno ou preparação antigênica de uma primeira cepa de influenza |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| NZ575271A (en) | 2006-09-11 | 2011-09-30 | Novartis Ag | Making influenza virus vaccines without using eggs |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
| EP2433648A3 (en) | 2006-10-12 | 2012-04-04 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
| JP2011506264A (ja) | 2006-12-06 | 2011-03-03 | ノバルティス アーゲー | インフルエンザウイルスの４つの株に由来する抗原を含むワクチン |
| US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
| PT2185191E (pt) | 2007-06-27 | 2012-11-27 | Novartis Ag | Vacinas contra a gripe com baixo teor de aditivos |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| JP5535910B2 (ja) * | 2007-08-28 | 2014-07-02 | バクスター・インターナショナル・インコーポレイテッド | ウイルスワクチンを生産する方法 |
| AU2008343745B2 (en) | 2007-10-01 | 2012-05-10 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| EP2235532B1 (en) * | 2007-12-24 | 2013-04-24 | Novartis AG | Assays for adsorbed influenza vaccines |
| US8506966B2 (en) * | 2008-02-22 | 2013-08-13 | Novartis Ag | Adjuvanted influenza vaccines for pediatric use |
| JP5518041B2 (ja) | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | インフルエンザウイルスワクチン抗原の調製における改良 |
| KR20110009157A (ko) | 2008-04-16 | 2011-01-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
| EP2361304A2 (en) | 2008-11-05 | 2011-08-31 | GlaxoSmithKline Biologicals S.A. | Novel method |
| WO2010092476A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| EA023662B1 (ru) | 2009-02-10 | 2016-06-30 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
| JP2012517416A (ja) * | 2009-02-10 | 2012-08-02 | ノバルティス アーゲー | 増加した量のｈ３抗原を含むインフルエンザワクチン |
| DE102010018462A1 (de) | 2009-04-27 | 2011-04-07 | Novartis Ag | Impfstoffe zum Schutz gegen Influenza |
| JP5836266B2 (ja) | 2009-05-21 | 2015-12-24 | ノバルティス アーゲー | 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学 |
| US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| MX2012000372A (es) | 2009-07-06 | 2012-02-28 | Variation Biotechnologies Inc | Metodos para preparar vesiculas y formulaciones producidas a partir de las mismas. |
| WO2011012999A1 (en) | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| KR20120083480A (ko) | 2009-10-20 | 2012-07-25 | 노파르티스 아게 | 바이러스 구제를 위한 개선된 역유전학 방법 |
| GB0918830D0 (en) * | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
| GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
| DE102009056871A1 (de) | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| CN102753149B (zh) | 2009-12-03 | 2015-10-14 | 诺华股份有限公司 | 乳液微流化和/或均化期间的组分循环 |
| ES2477230T3 (es) | 2009-12-03 | 2014-07-16 | Novartis Ag | Organización cámaras de interacción y de presión de retorno para la microfluidizaci�n |
| DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
| SG10201501612RA (en) | 2009-12-03 | 2015-04-29 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
| US20110305748A1 (en) | 2010-03-11 | 2011-12-15 | Immune Design, Corp. | Vaccines for Pandemic Influenza |
| JP6072677B2 (ja) | 2010-05-06 | 2017-02-01 | ノバルティス アーゲー | 微生物の不活化のための有機ペルオキシド化合物 |
| EP2620423B2 (en) | 2010-05-12 | 2019-07-31 | Novartis AG | Improved methods for preparing squalene |
| JP5876036B2 (ja) | 2010-05-21 | 2016-03-02 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| PL2575872T3 (pl) | 2010-06-01 | 2021-02-22 | Seqirus UK Limited | Zatężanie antygenów szczepionkowych grypy bez liofilizacji |
| WO2011154976A2 (en) | 2010-06-08 | 2011-12-15 | Panacea Biotec Limited | Improved influenza vaccine |
| CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
| CA2808965C (en) | 2010-08-20 | 2020-01-07 | Theraject, Inc. | Soluble needle arrays for delivery of influenza vaccines |
| AU2011300402B2 (en) | 2010-09-07 | 2015-01-22 | Novartis Ag | Generic assays for detection of mammalian reovirus |
| JP6045499B2 (ja) | 2010-10-27 | 2016-12-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 赤痢菌リポ多糖及び外膜タンパク質を含む免疫原性組成物 |
| US10736844B2 (en) | 2011-01-13 | 2020-08-11 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| AU2012205315B2 (en) | 2011-01-13 | 2017-05-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| JP5798356B2 (ja) * | 2011-04-06 | 2015-10-21 | 一般財団法人化学及血清療法研究所 | 新規インフルエンザワクチン安定化剤 |
| GB201216121D0 (en) | 2012-09-10 | 2012-10-24 | Novartis Ag | Sample quantification by disc centrifugation |
| EP2768528A1 (en) | 2011-10-20 | 2014-08-27 | Novartis AG | Adjuvanted influenza b virus vaccines for pediatric priming |
| WO2013072768A2 (en) | 2011-11-18 | 2013-05-23 | Variation Biotechnologies, Inc. | Synthetic derivatives of mpl and uses thereof |
| CA2894442C (en) | 2012-01-12 | 2020-01-21 | Variation Biotechnologies Inc. | Compositions and methods for treating viral infections |
| CA3207612A1 (en) | 2012-01-26 | 2013-08-01 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| EP4008354A1 (en) | 2012-01-27 | 2022-06-08 | Variation Biotechnologies Inc. | Methods and compositions for therapeutic agents |
| WO2013087945A2 (en) | 2012-03-02 | 2013-06-20 | Novartis Ag | Influenza virus reassortment |
| GB201205189D0 (en) | 2012-03-23 | 2012-05-09 | Glaxosmithkline Biolog Sa | Novel medical use |
| US20130315955A1 (en) * | 2012-04-13 | 2013-11-28 | Protein Sciences Corporation | Stability and potency of hemagglutinin |
| WO2013182498A1 (en) | 2012-06-04 | 2013-12-12 | Novartis Ag | Improved safety testing |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| US9708585B2 (en) | 2012-12-03 | 2017-07-18 | Seqirus UK Limited | Influenza virus reassortment |
| AU2014204826A1 (en) | 2013-01-10 | 2015-07-09 | Seqirus UK Limited | Influenza virus immunogenic compositions and uses thereof |
| CA2905612A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Influenza virus reassortment |
| JP2016521282A (ja) | 2013-05-10 | 2016-07-21 | ノバルティス アーゲー | インフルエンザワクチンにおけるナルコレプシーのリスクの回避 |
| DE202013005130U1 (de) | 2013-06-05 | 2013-09-10 | Novartis Ag | Influenza Virus Reassortierung |
| DE202013005100U1 (de) | 2013-06-05 | 2013-08-26 | Novartis Ag | Influenza Virus Reassortierung |
| CN105722976A (zh) | 2013-06-06 | 2016-06-29 | 诺华股份有限公司 | 流感病毒重配 |
| CN104436157A (zh) | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
| EP3075393A4 (en) * | 2013-11-29 | 2017-08-16 | Terumo Kabushiki Kaisha | Adjuvant composition, vaccine composition comprising same, and method for producing same |
| EP3226904B1 (en) | 2014-12-02 | 2019-03-06 | Novartis AG | Manufacture of surfactant-containing compositions |
| EP3294448A4 (en) | 2015-05-14 | 2018-12-12 | Longhorn Vaccines and Diagnostics, LLC | Rapid methods for the extraction of nucleic acids from biological samples |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| AU2016290603B2 (en) | 2015-07-07 | 2022-06-02 | Seqirus UK Limited | Influenza potency assays |
| WO2017167768A1 (en) | 2016-03-28 | 2017-10-05 | Glaxosmithkline Biologicals S.A. | Novel vaccine composition |
| GB201614799D0 (en) * | 2016-09-01 | 2016-10-19 | Glaxosmithkline Biologicals Sa | Compositions |
| AU2018309648B2 (en) | 2017-08-04 | 2024-10-31 | Syngenta Crop Protection Ag | Methods and compositions for targeted genomic insertion |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| EP3917567A1 (en) | 2019-01-30 | 2021-12-08 | GlaxoSmithKline Biologicals SA | Oil/surfactant mixtures for self-emulsification |
| WO2020219719A1 (en) | 2019-04-24 | 2020-10-29 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| EP4061930A1 (en) | 2019-11-18 | 2022-09-28 | Seqirus Pty Ltd | Method for producing reassortant influenza viruses |
| US12485166B2 (en) | 2020-02-06 | 2025-12-02 | Longhorn Vaccines And Diagnostics, Llc | Vaccines for the treatment and prevention of zoonotic infections |
| RU2754398C1 (ru) * | 2020-06-25 | 2021-09-01 | Общество с ограниченной ответственностью «ФОРТ» | Способ получения четырехвалентной вакцины для профилактики гриппа |
| WO2022003560A1 (en) | 2020-06-30 | 2022-01-06 | Seqirus UK Limited | Cold filtration of oil-in-water emulsion adjuvants |
| KR20230091978A (ko) | 2020-10-20 | 2023-06-23 | 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 | 면역원성 항원 |
| WO2025019631A1 (en) | 2023-07-19 | 2025-01-23 | Icahn School Of Medicine At Mount Sinai | Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520A (en) | 1848-04-18 | Oegan-pipb | ||
| US639A (en) | 1838-03-17 | of boston | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| DD155875A1 (de) | 1980-12-31 | 1982-07-14 | Willy Nordheim | Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| DD211444A3 (de) | 1982-08-19 | 1984-07-11 | Saechsisches Serumwerk | Verfahren zur herstellung von influenza-impfstoffen |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| DD300833A7 (de) | 1985-10-28 | 1992-08-13 | Saechsische Landesgewerbefoerd | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| NO902352L (no) * | 1989-05-29 | 1990-11-30 | Lion Corp | Fremgangsmaate for fremstilling av en vaksine mot dental karies, samt vaksineblandinger for anvendelse som nesedraaper |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| JP3723231B2 (ja) | 1991-12-23 | 2005-12-07 | ディミナコ アクチェンゲゼルシャフト | アジュバント |
| IL101007A (en) * | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| DE69313134T2 (de) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| KR100310510B1 (ko) | 1993-03-23 | 2002-07-04 | 장 스테판느 | 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물 |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5616487A (en) * | 1994-09-15 | 1997-04-01 | Aastrom Biosciences, Inc. | Stabilized retrovirus compositions |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| ATE214603T1 (de) | 1995-06-30 | 2002-04-15 | American Cyanamid Co | Stabile makrolide und makrolide imptstoff- zusammensetzungen |
| US20020165168A1 (en) | 1995-12-16 | 2002-11-07 | Joachim Bunger | Use of sugar derivatives as antimicrobial, antimycotic and/or antiviral active substances |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US5919480A (en) * | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
| US6403098B1 (en) * | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| DE19649895A1 (de) * | 1996-12-02 | 1998-06-04 | Henkel Kgaa | Schäumende Körperreinigungsmittel |
| CA2277911C (en) | 1997-01-13 | 2010-09-14 | Emory University | Compounds and their combinations for the treatment of influenza infection |
| GB9705740D0 (en) * | 1997-03-20 | 1997-05-07 | Medeva Europ Ltd | A method of preservation |
| AU743114B2 (en) | 1997-04-01 | 2002-01-17 | Corixa Corporation | Aqueous immunologic adjuvant compositions of monophosphoryl lipid A |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| GB9711990D0 (en) * | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
| EP1279401B1 (en) * | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| BR9909915A (pt) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Composições adjuvantes |
| FR2780278B1 (fr) * | 1998-06-24 | 2001-01-19 | Oreal | Composition conditionnante et detergente et utilisation |
| DE19841796A1 (de) * | 1998-09-12 | 2000-03-16 | Beiersdorf Ag | Kombinationen von Antiadhäsiva (Kohlenhydrate) und Mikrobiziden |
| DK1187629T3 (da) * | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| AUPQ233799A0 (en) * | 1999-08-19 | 1999-09-09 | Minister For Agriculture, Minister For Land And Water Conservation For And On Behalf Of The State Of New South Wales | Recombinant sub-unit vaccine |
| HK1049106A1 (zh) * | 1999-09-24 | 2003-05-02 | Smithkline Beecham Biologicals S.A. | 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途 |
| IL148671A0 (en) * | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| PL355287A1 (en) * | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| EP1225887A2 (en) | 1999-10-19 | 2002-07-31 | The Procter & Gamble Company | Antimicrobial compositions comprising pyroglutamic acid and optionally metal salts |
| US20040028698A1 (en) * | 2000-10-02 | 2004-02-12 | Colau Brigitte Desiree Alberte | Vaccine |
| WO2002067983A1 (en) * | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
| MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| US9856414B2 (en) | 2013-06-10 | 2018-01-02 | Dober Chemical Corp. | Compositions, systems and methods of making coated additive components |
-
2002
- 2002-05-28 MY MYPI20021956A patent/MY134424A/en unknown
- 2002-05-28 TW TW091111304A patent/TWI228420B/zh not_active IP Right Cessation
- 2002-05-29 WO PCT/EP2002/005883 patent/WO2002097072A2/en not_active Ceased
- 2002-05-29 CZ CZ20033253A patent/CZ298697B6/cs unknown
- 2002-05-29 EP EP12170561A patent/EP2495314A1/en not_active Withdrawn
- 2002-05-29 AT AT02743125T patent/ATE420159T1/de active
- 2002-05-29 CN CN2006101156101A patent/CN101069744B/zh not_active Expired - Lifetime
- 2002-05-29 KR KR1020037015649A patent/KR100871021B1/ko not_active Expired - Lifetime
- 2002-05-29 JP JP2003500240A patent/JP4074582B2/ja not_active Expired - Lifetime
- 2002-05-29 PL PL366990A patent/PL206435B1/pl unknown
- 2002-05-29 MX MXPA03010944A patent/MXPA03010944A/es active IP Right Grant
- 2002-05-29 ES ES02743125T patent/ES2318020T3/es not_active Expired - Lifetime
- 2002-05-29 AU AU2006200742A patent/AU2006200742C9/en active Active
- 2002-05-29 HU HU0400445A patent/HU229368B1/hu unknown
- 2002-05-29 CA CA2448208A patent/CA2448208C/en not_active Expired - Lifetime
- 2002-05-29 SI SI200230806T patent/SI1407008T1/sl unknown
- 2002-05-29 CN CNB028146557A patent/CN1279165C/zh not_active Expired - Lifetime
- 2002-05-29 PT PT02743125T patent/PT1407008E/pt unknown
- 2002-05-29 EP EP02743125A patent/EP1407008B1/en not_active Expired - Lifetime
- 2002-05-29 NZ NZ529755A patent/NZ529755A/en not_active IP Right Cessation
- 2002-05-29 BR BRPI0210076-2 patent/BRPI0210076B8/pt not_active IP Right Cessation
- 2002-05-29 DK DK02743125T patent/DK1407008T3/da active
- 2002-05-29 EP EP09100013A patent/EP2039761A1/en not_active Ceased
- 2002-05-29 AU AU2002344182A patent/AU2002344182C1/en not_active Expired
- 2002-05-29 US US10/480,952 patent/US7316813B2/en not_active Expired - Lifetime
- 2002-05-29 DE DE60230760T patent/DE60230760D1/de not_active Expired - Lifetime
- 2002-05-30 AR ARP020102018A patent/AR036039A1/es not_active Application Discontinuation
-
2003
- 2003-11-18 IL IL158931A patent/IL158931A/en active IP Right Grant
- 2003-11-24 NO NO20035208A patent/NO335212B1/no not_active IP Right Cessation
- 2003-11-27 ZA ZA2003/09250A patent/ZA200309250B/en unknown
- 2003-11-27 CO CO03104769A patent/CO5540349A2/es active IP Right Grant
-
2007
- 2007-10-18 US US11/874,647 patent/US20080181914A1/en not_active Abandoned
-
2008
- 2008-01-17 IL IL188834A patent/IL188834A/en active IP Right Grant
-
2009
- 2009-03-26 CY CY20091100357T patent/CY1108930T1/el unknown
-
2013
- 2013-12-18 FR FR13C0072C patent/FR13C0072I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0210076A8 (pt) | Preparação de vírus da influenza inativado, vacina de influenza, método para a preparação de um antígeno de hemaglutinina estável, e, uso de alfa-tocoferol ou succinato | |
| ES2357752T3 (es) | Reducción de riesgos latrogénicos potenciales asocidos con vacunas. | |
| BR112022024248A2 (pt) | Vacinas de combinação à base de ácido nucleico | |
| BR9911163A (pt) | Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo | |
| AU774921B2 (en) | Novel composition | |
| JP2004527264A5 (enExample) | ||
| ES2377761T3 (es) | Vacuna contra la gripe de emulsión de aceite en agua | |
| BR0014281A (pt) | Vacina contra vìrus de gripe intranasal | |
| BRPI0208183B8 (pt) | peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer | |
| BRPI0707300A8 (pt) | Vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica | |
| BR0208301A (pt) | Vacinas de ácido nucléico para prevenção de infecção por flavivìrus | |
| BR0114393A (pt) | Uso de uma preparação de vìrus envelopado dividido, método para produzir uma formulação de vacina intranasal, uso de uma preparação de vacina de vìrus envolopado dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por vìrus envelopado | |
| Zakhartchouk et al. | Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines | |
| de Bruijn et al. | Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly | |
| BR0207067A (pt) | Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo | |
| NO985821L (no) | Substituerte syklopentanforbindelser som er nyttige som neuraminidaseinhibitorer | |
| BRPI0407734A (pt) | derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo | |
| ATE214615T1 (de) | Impfstoffe gegen grippe | |
| BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
| BRPI0511776A (pt) | vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado | |
| BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
| NZ592713A (en) | Adjuvanted influenza vaccines including a cytokine-inducing agents other than an agonist of Toll-Like Receptor 9 | |
| BR0112497A (pt) | Antìgenos de streptococcus pyogenes | |
| BR9916893A (pt) | Tratamento | |
| EP1796720B1 (en) | Bivalent avian influenza vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 7/04 Ipc: C12N 7/04 (2006.01), A61K 39/145 (2006.01), A61P 3 |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: GLAXOSMITHKLINE BIOLOGICALS BRANCH OF SMITHKLINE B |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 29/05/2022 |